Biomica Ltd. today announced its CEO and VP R&D will both be participating in 7th Annual Microbiome Movement Drug Development Europe, taking place in London, UK, between January 31 and February 2, 2023.
| REHOVOT, Israel, Jan. 24, 2023 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced its CEO and VP R&D will both be participating in 7th Annual Microbiome Movement Drug Development Europe, taking place in London, UK, between January 31 and February 2, 2023.  The 7th Microbiome Movement – Drug Development Summit Europe aims to unite Europe’s leading drug developers and microbiome experts to share their latest discoveries on microbiome functionality, translation, clinical development, biomarker discovery and manufacturing scale-up. In attendance from Biomica will be CEO Dr. Elran Haber and VP R&D Dr. Shiri Meshner. Dr. Haber will take part in two industry panel discussions. These are entitled, “How to Turn Outstanding Microbiome Science into Effective & Efficient Products”, taking place on February 1, 2023, at 9:30am GMT and “Working with Microbiome Investors”, scheduled to take place later that day at 4:30pm GMT. Dr. Meshner will be presenting on February 1, 2023, at 2:55pm, and the presentation is entitled, “Rationally Designed LBPs – From Computational & Pre-clinical Data to Clinical Studies.” Dr. Haber and Dr. Meshner will both be available for one-on-one meetings at the conference, and those interested should be in touch with the investor or public relations team. About Biomica Biomica is a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics utilizing a dedicated Computational Predictive Biology platform (CPB), licensed from Evogene. Biomica aims to identify and characterize disease-related microbiome entities and to develop novel therapeutics based on these understandings. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. Biomica is a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN). For more information, please visit www.biomicamed.com. Logo - https://mma.prnewswire.com/media/1974949/Biomica.jpg Evogene Contacts: Public Relations: 
SOURCE Biomica Ltd. | ||
Company Codes: NASDAQ-NMS:EVGN, TelAviv:EVGN |
View original content:
